论文部分内容阅读
用单克隆抗体酶免疫法分别检测５０例及９０例不同病期肝、肾疾病患者血清Ⅳ型胶原（ＣＬ－Ⅳ）水平。旨在探讨作为细胞外基质成分ＣＬ－Ⅳ在这两类疾病发展及硬化过程中变化的意义。发现血清ＣＬ－Ⅳ在肝、肾疾病中有不同程度改变，并与疾病严重程度密切相关。提示ＣＬ－Ⅳ代谢变化可能在肝、肾疾病进行性发展及组织硬化过程中起重要作用。血清ＣＬ－Ⅳ浓度可作为临床监测和判断患者肝、肾功能损害程度、活动状态及组织硬化的一项常规辅助指标。
Monoclonal antibody enzyme immunoassay was used to detect serum level of type Ⅳ collagen (CL-Ⅳ) in 50 patients and 90 patients with different stages of liver and kidney disease. To explore the role of extracellular matrix components CL-Ⅳ in the development of these two types of disease and the significance of changes in the process of hardening. Serum CL-IV was found to have varying degrees of change in liver and kidney disease, and is closely related to the severity of the disease. These results suggest that CL-Ⅳ metabolic changes may play an important role in the progressive development of liver and kidney diseases and in the process of tissue sclerosis. Serum CL-IV concentration can be used as a routine auxiliary indicator for clinical monitoring and judging the degree of liver and kidney dysfunction, activity status and tissue sclerosis in patients.